日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer

III期EPIC试验的RAS扩展分析：伊立替康联合西妥昔单抗对比伊立替康作为转移性结直肠癌患者二线治疗方案

期刊:Oncologist
影响因子:4.2
doi:10.1002/onco.13591
Sobrero, Alberto; Lenz, Heinz-Josef; Eng, Cathy; Scheithauer, Werner; Middleton, Gary; Chen, Wenfeng; Esser, Regina; Nippgen, Johannes; Burris, Howard
RAS
肿瘤
肠癌
肿瘤免疫
发表日期：2021
文献求助 收藏

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors

一项针对既往接受过治疗的转移性胃肠道间质瘤患者的II期研究，评估人源抗PDGFRα单克隆抗体（olaratumab，IMC-3G3）的疗效。

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdw659
Wagner, A J; Kindler, H; Gelderblom, H; Schöffski, P; Bauer, S; Hohenberger, P; Kopp, H-G; Lopez-Martin, J A; Peeters, M; Reichardt, P; Qin, A; Nippgen, J; Ilaria, R L; Rutkowski, P
单克隆抗体
发表日期：2017
文献求助 收藏

Phase I study of olaratumab in Japanese patients with advanced solid tumors

olaratumab治疗日本晚期实体瘤患者的I期研究

期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.12444
Doi, Toshihiko; Ma, Yan; Dontabhaktuni, Aruna; Nippgen, Cornelia; Nippgen, Johannes; Ohtsu, Atsushi
发表日期：2014
文献求助 收藏

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

西妥昔单抗联合伊立替康/5-氟尿嘧啶/亚叶酸钙（FOLFIRI）方案一线治疗转移性结直肠癌：一项多中心两部分I/II期研究

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/1471-2407-9-112
Raoul, Jean-Luc; Van Laethem, Jean-Luc; Peeters, Marc; Brezault, Catherine; Husseini, Fares; Cals, Laurent; Nippgen, Johannes; Loos, Anja-Helena; Rougier, Philippe
肿瘤
肠癌
肿瘤免疫
发表日期：2009
文献求助 收藏

Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway

西伦吉肽通过抑制FAK/src/AKT通路，诱导内皮细胞和胶质瘤细胞脱落和凋亡。

期刊:Journal of Experimental & Clinical Cancer Research
影响因子:12.8
doi:10.1186/1756-9966-27-86
Oliveira-Ferrer, Leticia; Hauschild, Jessica; Fiedler, Walter; Bokemeyer, Carsten; Nippgen, Johannes; Celik, Ilhan; Schuch, Gunter
凋亡
表观遗传
细胞生物学
FAK
信号转导
内皮细胞
胶质瘤
AKT
发表日期：2008
文献求助 收藏

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

一项随机多中心II期临床试验，比较血管生成抑制剂西伦吉肽（EMD 121974）联合吉西他滨与单用吉西他滨治疗晚期不可切除胰腺癌的疗效。

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/1471-2407-6-285
Friess, Helmut; Langrehr, Jan M; Oettle, Helmut; Raedle, Jochen; Niedergethmann, Marco; Dittrich, Christian; Hossfeld, Dieter K; Stöger, Herbert; Neyns, Bart; Herzog, Peter; Piedbois, Pascal; Dobrowolski, Frank; Scheithauer, Werner; Hawkins, Robert; Katz, Frieder; Balcke, Peter; Vermorken, Jan; van Belle, Simon; Davidson, Neville; Esteve, Albert Abad; Castellano, Daniel; Kleeff, Jörg; Tempia-Caliera, Adrien A; Kovar, Andreas; Nippgen, Johannes
肿瘤
肿瘤免疫
EMD
胰腺癌
血管生成
发表日期：2006
文献求助 收藏